The Feinstein Institute for Medical Research is a private, non-profit institution with research programs focusing on immunology, inflammation, neuroscience, and behavioral medicine. The mission is to produce knowledge that will change the way medicine is practiced. It employs >800 scientists, clinical researchers, and staff.
| The Feinstein Institute for Medical Research | |
|---|---|
| Established | 1995 |
| Chairman | Ralph Nappi |
| Dean | Bettie Steinberg |
| Location | Manhasset, New York, United States |
| Website | http://www.feinsteininstitute.org |
Contents |
The Institute was founded in 1995 to support the research operations of the North Shore-LIJ Health System. North Shore University Hospital, in Manhasset, NY, originally constructed a research building in 1985 to foster clinical and translational science. Clinical research at North Shore University Hospital underwent significant expansion at this time, highlighted by the addition of new laboratories and investigators, and new technology, including one of the earliest MRI scanners in New York State, and a PET scanner and cyclotron facility that was first on the east coast. By 2010 Feinstein researchers had expanded operations to receive >$45M in federal funding from the National Institutes of Health in order to identify disease mechanisms and drug targets. Their clinical research program annually enrolls >10,000 subjects into clinical research programs.
Feinstein investigators study the molecular biology and pathophysiology of immunity, autoimmune diseases, cancer, neurodegenerative diseases and neuropsychiatric conditions. They collaborate with other Universities worldwide, and have established an inter-institutional training affiliation with the Karolinska Institute in Stockholm, Sweden. Investigators also collaborate with clinicians in the North Shore-LIJ Health System (including North Shore University Hospital and Long Island Jewish Medical Center) to identify the underlying mechanisms of disease. Patients participate in clinical trials related to the use of experimental drugs that are in various stages of clinical and preclinical testing for cancer, cardiac disease, diabetes, sepsis, shock, trauma, arthritis, and other inflammatory conditions. The volume of National Institutes of Health-funded, patient-oriented research programs in the Feinstein Institute is significant: >90% of the research is categorized as "patient-oriented research," and 65% of these projects are supported by federal grants. The Feinstein is also home to an NIH-funded General Clinical Research Center that offers state-of-the-art facilities for designing, implementing and conducting clinical research studies in a central location; an NIH-funded Early-Phase Schizophrenia Center focuses on the development of the best treatments for schizophrenia; and the Laboratory of Medicinal Biochemistry, which focuses on synthesis of novel molecules as experimental therapeutics, to streamline preclinical testing. It is also home to the Litwin-Zucker Center[1] [2] [3]for Alzheimer's Disease, one of the premier research institutes in the United States.
The Feinstein is the laboratory and faculty home of the Elmezzi Graduate School of Molecular Medicine, an independent, degree-granting institution, chartered by the State University of New York. It confers the PhD degree in Molecular Medicine to students who have previously completed medical school, and then matriculate in a mentored research training program in the Feinstein labs.
The Feinstein publishes Molecular Medicine, an international, peer-reviewed journal that reports on fast-breaking developments in the field of molecular medicine. Its impact factor is ranked in the top 6% of all peer-reviewed journals in biomedical science.